论文部分内容阅读
１９８７年至１９８９年采用前瞻性随机研究治疗鼻咽癌２１７例。分为二组，直线加速器（８ｍｖ－ｘ）组１０７例，６０Ｃｏ组１１０例，两组年龄、性别、临床分期、治疗方法、时间剂量等因素基本相同。全组５年随访率为９０％，３、５年生存率分别为６０．８％和４３．８％，８ｍｖ－ｘ组分别为６７．３％和４９．５％，６０Ｃｏ组为５４．５％和３８．２％，８ｍｖ－ｘ组较６０Ｃｏ组稍好，但无统计学差异（Ｐ＞０．０５）．疗终颈部淋巴结残存率和原发灶复发率８ｍｖ－ｘ组为２５．６％和１１．２％。６０Ｃｏ组为３４．９％和１２．７％（Ｐ＞０．０５）。
From 1987 to 1989, 217 cases of nasopharyngeal carcinoma were treated with prospective randomized study. There were 107 patients in the linear accelerator (8mv-x) group and 110 patients in the 60Co group. The two groups were basically the same in terms of age, sex, clinical stage, treatment method and time dosage. The overall 5-year follow-up rate was 90%, the 3-year and 5-year survival rates were 60.8% and 43.8% respectively, 67.3% and 49.5% in the 8mv-x group and 54.5% in the 60Co group % And 38.2%, 8mv-x group slightly better than 60Co group, but no statistical difference (P> 0.05). The survival rate of residual lymph nodes and the recurrence rate of primary tumors were 25.6% and 11.2% in 8mv-x group. The 60Co group was 34.9% and 12.7% (P> 0.05).